AMA2 vs Genomi

AMA2 and Genomi are both agent frameworks tracked by AIDiveForge. Below is a side-by-side comparison of pricing, capabilities, platforms, and ownership — sourced from each tool's live website and verified before publishing.

AMA2

AMA2 gives agents a native place in a shared thread — same participant model, same permissions, same persistent context — instead of bolting them on as integrations. The vendor describes a setup flow through a CLI and an MCP server connection, so agents slot into tools like Claude Code or Cursor without a separate API integration per agent. Where this hits a wall: AMA2 is infrastructure, not an agent runtime, so teams that need agents to plan and execute multi-step tasks independently still build that logic elsewhere. The shared-thread model works well when people and agents need to stay in the same conversation; it does not replace an orchestration layer for autonomous task pipelines.

Genomi

The core workflow is four steps: install the agent harness, point it at your raw genome file on disk, build a local SQLite index, then ask questions through whichever AI agent you already run — Claude Code, Cursor, Gemini CLI, Goose, and others are listed as compatible. Pharmacogenomics, carrier status, polygenic risk scores, nutrigenomics, and ancestry PCA projection are all covered through distinct skill modules backed by ClinVar, PharmCAT, PGS Catalog, HPO, GenCC, and 1000 Genomes reference data. The privacy architecture is explicit: raw genome data stays on disk, and only the specific evidence snippets relevant to a query cross the boundary to whatever LLM handles the response. The vendor marks this as experimental and not for clinical use — which means researchers and privacy-conscious individuals exploring personal data are the intended audience, not clinical teams expecting diagnostic-grade output.

Attribute	AMA2	Genomi
Pricing	Paid	Free
Price	$10/mo	—
Free trial	No	No
Open source	No	Yes
Has API	Yes	No
Self-hosted option	No	Yes
Platforms	—	Linux, macOS, Windows (Python-based)
Released	—	2024
Pros	Agents join threads with the same participant and permission model as people, so you avoid the context reconstruction overhead that comes with every webhook-based agent call. Native persistent thread context for agents, which means agents do not lose conversation state between turns the way stateless bot integrations do. MCP server connection point means agents plug in through the tool they already use — Claude Code, Cursor, Gemini CLI — rather than requiring a separate per-agent API integration. Named role slots per agent (reply-enabled, observer) in a thread, so you get access control per participant without building a permission layer yourself. API access is available, so teams can build against AMA2 programmatically rather than being locked to the CLI-and-MCP path.	Local-first data architecture keeps the raw genome file on disk and only sends queried evidence snippets to the LLM, so teams with strict data policies can explore personal genomic data without uploading a single variant to a third-party server. Skill modules cover pharmacogenomics via PharmCAT and ClinPGx, carrier status via ClinVar and HPO, polygenic risk via PGS Catalog, and ancestry via 1000 Genomes PCA — so a researcher doesn't have to stitch together five separate tools and manually reconcile their outputs. Each answer carries source attribution and stated evidence limits, which means you can trace a finding back to ClinVar or GenCC rather than accepting a response with no provenance — a real gap in generic LLM genomic Q&A. Agent-agnostic MCP and skills-host architecture plugs into whichever AI agent a team already runs, so there is no forced migration to a new interface or locked-in model provider. Apache-2.0 open-source license with self-hosted deployment means developers building agent-based genomic analysis tools can inspect, modify, and extend the skill layer without negotiating commercial terms.
Cons	AMA2 is a messaging runtime, not an agent executor — it has no task planning or execution logic. Teams that need agents to run autonomous multi-step workflows build that logic in a separate system and use AMA2 only for the communication layer, which means two systems to maintain from the start. No self-hosted option exists. Teams operating in environments with strict data residency requirements or internal network policies cannot run AMA2 on their own infrastructure — those teams move to a self-hostable alternative rather than waiting for a deployment option the vendor has not announced. The product is in beta, and the vendor states it is free during that period — which means the pricing and feature boundaries for paid tiers, and any breaking changes to the MCP integration, are not yet fixed. Teams building production workflows on AMA2 are building on a moving target.	Installation requires following a source-code setup guide and configuring an AI agent to connect to the harness — non-technical users hit a wall before they ask a single question, and there is no hosted web interface to fall back on. The project is vendor-labeled experimental, which means skill coverage, reference database freshness, and edge-case handling are not production-guaranteed; teams relying on consistent outputs for any regulated or clinical-adjacent workflow will find the absence of validation documentation disqualifying and will move to a certified clinical genomics platform instead. There is no hosted API, so teams building products that need to serve genomic queries to end users must provision and maintain their own infrastructure — at scale, that maintenance burden is not accounted for in the zero-cost licensing. Evidence snippets sent to an external LLM during a query still cross a data boundary, even if the raw genome file stays local; teams operating under strict genomic data agreements need to verify that snippet-level transmission satisfies their compliance posture before deploying, and the tool provides no compliance documentation to support that review.

Bottom line

AMA2 is paid while Genomi is free; Genomi is open source; only AMA2 exposes a public API. Choose based on which difference matters most for your workflow.

Frequently asked questions

What is the difference between AMA2 and Genomi?

AMA2 is Paid, while Genomi is Free and open source. Compare pricing, free trial, API, platforms, and pros/cons in the table above on AIDiveForge.

Is AMA2 better than Genomi?

It depends on your workflow. Use the side-by-side attributes (pricing, open source, API, self-hosted, platforms) to decide. AIDiveForge does not rank a universal winner — we publish verified facts so you can choose.

AMA2 vs Genomi: which should I pick?

Pick AMA2 if its pricing model, openness, or platform fit matches your constraints; pick Genomi otherwise. Check free-trial availability on each listing if you want to test before committing.

Comparison data is sourced and verified by the AIDiveForge data pipeline. AIDiveForge is editorially independent.